Xiaochun Hu, Ningyi Jiang, Jingyan Li, Hong Zhang, Sheng Liu, Xianping Lu, Jiugen Liang, Zhanlei Zhang. Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J]. Int J Radiat Med Nucl Med, 2015, 39(2): 140-143. DOI: 10.3760/cma.j.issn.1673-4114.2015.02.008
Citation: Xiaochun Hu, Ningyi Jiang, Jingyan Li, Hong Zhang, Sheng Liu, Xianping Lu, Jiugen Liang, Zhanlei Zhang. Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J]. Int J Radiat Med Nucl Med, 2015, 39(2): 140-143. DOI: 10.3760/cma.j.issn.1673-4114.2015.02.008

Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I

  • Objective To explore the effect of additional selenium on the serum levels of thyroid peroxidase antibody(TPOAb) after treatment of Graves disease with 131I.
    Methods A total of 266 patients with TPOAb levels between 10 and 1300 IU/ml participated in this study. TPOAb levels within 10 IU/ml to 60 IU/ml were considered negative, and levels greater than 60 IU/ml were considered positive. All patients were randomly divided into control(n=112) and selenium treatment group(n=154). After treatment with 131I, the control group received conventional therapy, whereas the selenium treatment group received additional selenium(100 μg twice a day). The TPOAb levels and positive ratios of the two groups were compared with pre-therapy levels after treatment for 6 and 12 months.
    Results After 6 months, the TPOAb levels in both groups significantly increased compared with the pre-therapy levels(control group:Z=-2.084, P < 0.05; selenium treatment group:Z=-2.112, P < 0.05). However, no significant difference existed in the TPOAb levels between the two groups(Z=-0.764, P > 0.05). After 12 months, the TPOAb levels in the control group did not change significantly compared with the pre-therapy levels(Z=-1.538, P > 0.05), whereas the TPOAb levels in the selenium treatment group significantly decreased compared with the pre-therapy levels(Z=-5.465, P < 0.01). The difference between the two groups were statistically significant(Z=-2.180, P < 0.05). The positive ratios of TPOAb for both groups did not change significantly 6 or 12 months after 131I therapy(control group:x12= 0.720, x22=0.103, both P > 0.05; selenium treatment group:x12=0.023, x22=0.340, both P > 0.05). Overall, the positive ratios were not statistically significant between the two groups(x12=0.001, x22=0.366, both P > 0.05).
    Conclusion Additional treatment with selenium after 131I therapy for Graves disease can effectively decrease the TPOAb levels, especially for patients with high initial TPOAb levels.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return